FR2493312B1 - - Google Patents

Info

Publication number
FR2493312B1
FR2493312B1 FR8114505A FR8114505A FR2493312B1 FR 2493312 B1 FR2493312 B1 FR 2493312B1 FR 8114505 A FR8114505 A FR 8114505A FR 8114505 A FR8114505 A FR 8114505A FR 2493312 B1 FR2493312 B1 FR 2493312B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR8114505A
Other languages
French (fr)
Other versions
FR2493312A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biorex Laboratories Ltd
Original Assignee
Biorex Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Laboratories Ltd filed Critical Biorex Laboratories Ltd
Publication of FR2493312A1 publication Critical patent/FR2493312A1/fr
Application granted granted Critical
Publication of FR2493312B1 publication Critical patent/FR2493312B1/fr
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/06Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
    • C07C245/08Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with the two nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings, e.g. azobenzene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09BORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B29/00Monoazo dyes prepared by diazotising and coupling
    • C09B29/10Monoazo dyes prepared by diazotising and coupling from coupling components containing hydroxy as the only directing group
    • C09B29/12Monoazo dyes prepared by diazotising and coupling from coupling components containing hydroxy as the only directing group of the benzene series
    • C09B29/14Hydroxy carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR8114505A 1980-07-21 1981-07-21 Derives de l'acide 2-hydroxy-5-phenylazobenzoique, leur procede de preparation et leurs applications en therapeutique Granted FR2493312A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8023826 1980-07-21

Publications (2)

Publication Number Publication Date
FR2493312A1 FR2493312A1 (fr) 1982-05-07
FR2493312B1 true FR2493312B1 (US20030199744A1-20031023-C00003.png) 1984-09-21

Family

ID=10514924

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8114505A Granted FR2493312A1 (fr) 1980-07-21 1981-07-21 Derives de l'acide 2-hydroxy-5-phenylazobenzoique, leur procede de preparation et leurs applications en therapeutique

Country Status (8)

Country Link
US (1) US4412992A (US20030199744A1-20031023-C00003.png)
JP (1) JPS5753449A (US20030199744A1-20031023-C00003.png)
DE (1) DE3128819A1 (US20030199744A1-20031023-C00003.png)
FR (1) FR2493312A1 (US20030199744A1-20031023-C00003.png)
HK (1) HK31885A (US20030199744A1-20031023-C00003.png)
IT (1) IT1138450B (US20030199744A1-20031023-C00003.png)
MY (1) MY8600029A (US20030199744A1-20031023-C00003.png)
SG (1) SG6885G (US20030199744A1-20031023-C00003.png)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981002671A1 (en) * 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
US4960765A (en) * 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
EP0039306B1 (de) * 1980-03-28 1984-01-11 Ciba-Geigy Ag Neue Azofarbstoffe, Verfahren zu deren Herstellung und deren Verwendung
SE8405924L (sv) * 1984-11-23 1986-05-24 Pharmacia Ab Nya azoforeningar
US4975233A (en) * 1988-12-09 1990-12-04 Hoechst Celanese Corporation Method of producing an enhanced polyester copolymer fiber
US5064637A (en) * 1989-05-30 1991-11-12 Board Of Regents, The University Of Texas System Substituted sulfonamide derivatives which inhibit allergic reactions
JPH0586844U (ja) * 1992-05-01 1993-11-22 株式会社柴崎製作所 ピルファープルーフキャップ
US5498608A (en) * 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
SE9700934D0 (sv) 1997-03-14 1997-03-14 Astra Ab New formulation
US6114382A (en) * 1998-11-11 2000-09-05 Moretti; Itagiba G. Methods for treating inflammatory bowel disease
JP4163946B2 (ja) 2000-08-29 2008-10-08 バイオコン・リミテッド 免疫調節性化合物およびその誘導体並びにそれを用いて疾患を治療する方法
JP5112595B2 (ja) * 2000-08-29 2013-01-09 バイオコン・リミテッド 抗炎症活性および抗生物質活性を有する5−asa誘導体およびこれを用いて疾患を治療する方法
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
PL2361620T3 (pl) 2004-02-06 2016-12-30 Zastosowanie aminosalicylanów w zespole jelita drażliwego z dominującą postacią biegunkową
EP1737469B1 (en) * 2004-03-23 2018-08-15 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20080306029A1 (en) * 2004-05-28 2008-12-11 Salix Pharmaceuticals, Inc. Prevention, Treatment, and Amelioration of Radiation Induced Enteritis
US7932366B2 (en) * 2004-07-07 2011-04-26 Biocon Limited Synthesis of azo bonded immunoregulatory compounds
WO2006125293A1 (en) * 2005-05-27 2006-11-30 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
US7741359B2 (en) * 2005-05-27 2010-06-22 Antibe Therapeutics Inc. Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
US7498355B2 (en) 2005-05-27 2009-03-03 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
US8921344B2 (en) 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CA2816276A1 (en) * 2005-08-24 2007-03-01 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture and use thereof
JP5421098B2 (ja) * 2006-06-06 2014-02-19 ジーアイケア ファーマ インク. トリメブチン及びn−脱メチル化トリメブチンの塩類
US7271253B1 (en) 2006-08-10 2007-09-18 Apotex Pharmachem Inc. Safe process for the preparation of balsalazide
AU2008347024A1 (en) 2007-10-19 2009-07-16 Omm Scientific, Inc. Methods of inhibiting bacterial virulence and compounds relating thereto
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
CN102627624B (zh) * 2012-04-25 2014-03-19 西南大学 4-(4-氨基苯磺酰胺基)苯乙酸衍生物及其制备方法和应用
WO2013167985A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
US9642915B2 (en) 2012-05-07 2017-05-09 Cellix Bio Private Limited Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
CN104583182A (zh) 2012-05-23 2015-04-29 塞利克斯比奥私人有限公司 用于治疗粘膜炎的组合物和方法
CN104603100A (zh) 2012-05-23 2015-05-06 塞利克斯比奥私人有限公司 用于治疗炎症性肠病的组合物和方法
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
JP2015529218A (ja) 2012-09-08 2015-10-05 セリックスビオ プライヴェート リミテッド 炎症と脂質障害の治療のための組成物及び方法
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (en) 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CN104974061B (zh) * 2014-04-14 2017-11-14 辽宁省药物研究院 一种巴柳氮钠的制备方法
NZ736131A (en) 2014-09-26 2019-04-26 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
CA2967908C (en) 2014-09-29 2020-11-17 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
ES2905771T3 (es) 2015-01-06 2022-04-12 Cellix Bio Private Ltd Composiciones y procedimientos para el tratamiento de la inflamación y del dolor
CN110003044A (zh) * 2019-04-26 2019-07-12 赤峰蒙欣药业有限公司 一种巴柳氮钠的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE353537B (US20030199744A1-20031023-C00003.png) * 1970-03-06 1973-02-05 Pharmacia Ab
US4045429A (en) * 1970-03-06 1977-08-30 Pharmacia Aktiebolag 4-(4-Hydroxy- or acetoxy-3-carbomethoxyphenylazo)-benzenesulphonyl chloride
BE791889A (fr) * 1971-11-26 1973-05-24 Pharmacia Ab Nouveaux derives de la pyridine
FR2212391B1 (US20030199744A1-20031023-C00003.png) * 1972-12-28 1976-06-04 Ugine Kuhlmann

Also Published As

Publication number Publication date
MY8600029A (en) 1986-12-31
IT8122859A0 (it) 1981-07-10
US4412992A (en) 1983-11-01
IT1138450B (it) 1986-09-17
FR2493312A1 (fr) 1982-05-07
SG6885G (en) 1985-06-14
DE3128819A1 (de) 1982-04-15
HK31885A (en) 1985-05-03
JPS6225656B2 (US20030199744A1-20031023-C00003.png) 1987-06-04
DE3128819C2 (US20030199744A1-20031023-C00003.png) 1990-02-15
JPS5753449A (en) 1982-03-30

Similar Documents

Publication Publication Date Title
DE3104108C2 (US20030199744A1-20031023-C00003.png)
FR2475760B3 (US20030199744A1-20031023-C00003.png)
DE3111126C2 (US20030199744A1-20031023-C00003.png)
FR2475770B1 (US20030199744A1-20031023-C00003.png)
DE3120690C2 (US20030199744A1-20031023-C00003.png)
FR2475980B3 (US20030199744A1-20031023-C00003.png)
CH627610B (US20030199744A1-20031023-C00003.png)
FR2474378B1 (US20030199744A1-20031023-C00003.png)
DE3153680A1 (US20030199744A1-20031023-C00003.png)
DE3103149C2 (US20030199744A1-20031023-C00003.png)
FR2474789B1 (US20030199744A1-20031023-C00003.png)
DE3148082C2 (US20030199744A1-20031023-C00003.png)
FR2474276B3 (US20030199744A1-20031023-C00003.png)
FR2474325B3 (US20030199744A1-20031023-C00003.png)
FR2475700B1 (US20030199744A1-20031023-C00003.png)
FR2476091B1 (US20030199744A1-20031023-C00003.png)
FR2476491B1 (US20030199744A1-20031023-C00003.png)
FR2474566B1 (US20030199744A1-20031023-C00003.png)
FR2475982B3 (US20030199744A1-20031023-C00003.png)
FR2476695B1 (US20030199744A1-20031023-C00003.png)
FR2475441B1 (US20030199744A1-20031023-C00003.png)
FR2476768B1 (US20030199744A1-20031023-C00003.png)
FR2474757B1 (US20030199744A1-20031023-C00003.png)
FR2474753B1 (US20030199744A1-20031023-C00003.png)
FR2474827B1 (US20030199744A1-20031023-C00003.png)

Legal Events

Date Code Title Description
TP Transmission of property